Figure 7: GSK3-inhibited NK cells show high activity in AML mouse model systems.

(a,b) NSG mice were injected with OCI-AML3 cells followed by weekly injections of vehicle, expanded NK cells, or expanded NK cells that were pre-treated with SB for 16 h. The per cent human AML cells (CD56⁻ CD45⁺) were detected by flow cytometry from (a) spleen and (b) bone marrow after 6 weeks (c) NSG mice were injected with primary AML cells followed by weekly injections of vehicle, expanded NK cells, or expanded NK cells that were pre-treated with compound 117 for 16 h. The per cent human AML cells (CD56⁻ CD45⁺) were detected by flow cytometry from the bone marrow after 5 weeks. (unpaired Student’s t-test ***P<0.001, **P<0.01). (d) NSG mice were injected with primary human AML cells followed by four (bi-weekly) injections of vehicle, expanded NK cells or expanded NK cells pre-treated with compound 117 for 16 h. Kaplan–Meier survival curves of mice are shown. χ² log-rank test was performed for statistical significance. **P<0.01 for AML+NK versus AML+ (NK+117) groups. Experiments is performed two times. In all mice experiments, five mice per group were used.